News & Analysis on Clinical Trial Services & Contract Research And Development
PEOPLE ON THE MOVE
Axel Wiest joins Board of Directors at Biosys
By Dani Bancroft
- Last updated on
Axel Wiest, the SVP/COO R&D and Head of Global Strategy and Business Operations R&D at Merck Biopharma, has been appointed to the board of Directors at Biosys UK Ltd.
Biosys is a clinical-stage microbiome company dedicated to the development of targeted oral immune therapies that modulate the gut microbiome, initially focused on the treatment of C. difficile infection.
Previously Axel was VP for Strategy and Project Management at Boehringer Ingelheim Biopharmaceuticals division for Contract Manufacturing, NBE and Biosimilar process development and manufacturing.
He also served as COO at Fresenius Biotech GmbH and President of Fresenius Biotech North America Inc.